Singapore markets open in 4 minutes

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
130.72+3.72 (+2.93%)
At close: 04:02PM EDT
130.90 +0.18 (+0.14%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close127.00
Open129.69
Bid130.65 x 900
Ask130.90 x 800
Day's range128.76 - 132.80
52-week range99.14 - 133.10
Volume12,739,818
Avg. volume8,364,783
Market cap331.118B
Beta (5Y monthly)0.40
PE ratio (TTM)933.71
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.08 (2.43%)
Ex-dividend date14 Mar 2024
1y target estN/A
  • Yahoo Finance Video

    Merck raises 2024 guidance on cancer drug demand

    Shares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading the pharmaceutical giant to raise its 2024 outlook. The company's performance was driven by strong demand for its cancer drug Keytruda. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith

  • Benzinga

    Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook

    On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me

  • Zacks

    Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

    Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.